Enzyme-free and label-free strategy for electrochemical oxaliplatin aptasensing by using rGO/MWCNTs loaded with AuPd nanoparticles as signal probes and electro-catalytic enhancers.

Autor: El-Wekil MM; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Assiut University, Assiut, Egypt. Electronic address: mohamed.mohamoud@ymail.com., Darweesh M; Department of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden; Department of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Egypt., Shaykoon MSA; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Egypt., Ali R; Department of Pharmaceutical Analytical Chemistry, Faculty of Pharmacy, Al-Azhar University, Assiut Branch, Egypt.
Jazyk: angličtina
Zdroj: Talanta [Talanta] 2020 Sep 01; Vol. 217, pp. 121084. Date of Electronic Publication: 2020 Apr 25.
DOI: 10.1016/j.talanta.2020.121084
Abstrakt: An innovative label free electrochemical aptasensor was developed for the analysis of oxaliplatin (OXAL) for the first time. The DNA oligonucleotide (aptamer) was successfully fabricated, by covalently attaching the amino terminus of the functional DNA on the glassy carbon electrode (GCE) surface modified with reduced graphene oxide (rGO) and multi-walled carbon nanotubes (MWCNTs) loaded with AuPd nanoparticles (AuPd NPs@rGO/MWCNTs/GCE). The stepwise assembly process of aptasensor on AuPd NPs@rGO/MWCNTs/GCE was characterized by electrochemical impedance spectroscopy (EIS) and cyclic voltammetry (CV). The aptamer-OXAL complex formation led to inhibition the electron transfer of Fe(CN) 6 3-/4- on the electrode interface, which was clearly observed by decreasing the peak current of the redox probe. Furthermore, we managed to quantitatively measure OXAL by adding different concentrations of OXAL, while monitoring the decrease of differential pulse voltammogram (DPV) responses of the redox probe. Under the optimized conditions, the electrochemical aptasensor exhibited a linear range of 0.1-170.0 nmol L -1 with LOD of 60.0 pmol L -1 . Next, we successfully applied the aptasensor calibrated system to determine OXAL in pharmaceutical injection and human biological samples.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Acknowledgement.
(Copyright © 2020 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: